Related Experiment Video
Updated: Jun 15, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol
Masayo Matsura1, Yoshihiro Fujiwara, Hiroshi Ito
1Department of Anesthesiology, Aichi Gakuin University School of Dentistry, Nagoya, Japan.
Objective:
The objective of this study was to determine if landiolol, ultra short-acting beta adrenoceptor antagonist, attenuates the prolongation of QT interval caused by electroconvulsive therapy (ECT).
Methods:
Fifteen patients, scheduled to undergo ECT for the treatment of major depression disorder, were studied. In each patient, 2 sessions of ECT were picked up and randomly assigned to be administered with (treatment L) or without continuous infusion of landiolol (treatment C). Electroconvulsive therapy was administered under general anesthesia with propofol and suxamethonium. Raw electrocardiogram waves were obtained from anesthesia monitor and stored on a personal computer. Automated electrocardiogram analyzing software was used for the determination of QT interval.
Results:
The increase in corrected QT caused by suxamethonium was significantly smaller in treatment L (36.8 +/- 14.5 ms for treatment C vs 17.9 +/- 6.5 ms for treatment L; P < 0.001). The increase in corrected QT caused by ECT was also smaller in treatment L (72.3 +/- 23.1 ms for treatment C vs 54.6 +/- 17.9 ms for treatment L; P = 0.02).
Conclusions:
The prolongation of QT interval caused by SUX and ECT was partially attenuated by landiolol.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Electroconvulsive Therapy
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
